iShares Core MSCI EAFE ETF vs uniQure N.V. Ordinary Shares — how do they compare? iShares Core MSCI EAFE ETF trades at $95.53 (market cap $188.94B), while uniQure N.V. Ordinary Shares trades at $20.78 (market cap $1.48B). The key difference: iShares Core MSCI EAFE ETF is far larger — about 127.7× uniQure N.V. Ordinary Shares's market cap, and iShares Core MSCI EAFE ETF is trading nearer its 52-week high, uniQure N.V. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core MSCI EAFE ETF for 41 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| IEFA | QURE | |
|---|---|---|
Market Cap | $188.94B | $1.48B |
Volume | 6,200,262 | 2,488,780 |
Sector | Broad Market / Factor | Health |
52-Week High | $101.41 | $70.59 |
52-Week Low | $85.06 | $9.03 |
Typical Hold Time | 41 Days | 0 Days |
Enterprise Value | — | $728.62M |
Signals from Pluang's Aura AI — not financial advice
IEFA, the iShares Core MSCI EAFE ETF, trades at $96.64, up 0.48% on the day, while technical indicators signal a bearish trend with moving averages and ADX pointing lower. The ETF provides exposure to developed markets outside North America, managing $196 billion in assets. Recent news highlights its size advantage and higher dividend yield compared to peers, though some competitors have shown stronger recent returns.
The outlook for IEFA is mixed, with bearish technicals offset by its low-cost, diversified international exposure. Opportunities include defensive shifts in investor flows away from concentrated U.S. tech, while risks involve underperformance versus broader global funds and capped upside in strategies like covered calls on the ETF.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →